Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer
BACKGROUND: We report long-term efficacy and cardiac safety outcomes in patients with HER2-positive early breast cancer treated with neoadjuvant pertuzumab plus trastuzumab with anthracycline-containing or anthracycline-free chemotherapy. - METHODS: Descriptive efficacy analyses were conducted in pa...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
January 2018
|
| In: |
European journal of cancer
Year: 2018, Volume: 89, Pages: 27-35 |
| ISSN: | 1879-0852 |
| Online Access: |
|
| Author Notes: | Andreas Schneeweiss, Stephen Chia, Tamas Hickish, Vernon Harvey, Alexandru Eniu, Maeve Waldron-Lynch, Jennifer Eng-Wong, Sarah Kirk, Javier Cortés |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1694146022 | ||
| 003 | DE-627 | ||
| 005 | 20240405193212.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200406s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2017.10.021 |2 doi | |
| 035 | |a (DE-627)1694146022 | ||
| 035 | |a (DE-599)KXP1694146022 | ||
| 035 | |a (OCoLC)1341313922 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 245 | 1 | 0 | |a Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study |b evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer |c Andreas Schneeweiss, Stephen Chia, Tamas Hickish, Vernon Harvey, Alexandru Eniu, Maeve Waldron-Lynch, Jennifer Eng-Wong, Sarah Kirk, Javier Cortés |
| 264 | 1 | |c January 2018 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 06.04.2020 | ||
| 520 | |a BACKGROUND: We report long-term efficacy and cardiac safety outcomes in patients with HER2-positive early breast cancer treated with neoadjuvant pertuzumab plus trastuzumab with anthracycline-containing or anthracycline-free chemotherapy. - METHODS: Descriptive efficacy analyses were conducted in patients randomised to group A (cycles 1-6: trastuzumab [8 mg/kg loading dose and 6 mg/kg maintenance] plus pertuzumab [840 mg loading dose and 420 mg maintenance], plus 5-fluorouracil, epirubicin and cyclophosphamide [FEC] [cycles 1-3; 500 mg/m2 5-fluorouracil/100 mg/m2 epirubicin/600 mg/m2 cyclophosphamide] then docetaxel [cycles 4-6; 75 mg/m2, escalated to 100 mg/m2 if well tolerated]), B (cycles 1-3: FEC, cycles 4-6: trastuzumab plus pertuzumab plus docetaxel as mentioned previously) or C (cycles 1-6: trastuzumab plus pertuzumab plus docetaxel [75 mg/m2, without dose escalation], and carboplatin [AUC 6]), five years after randomisation of the last patient. This study is registered with ClinicalTrials.gov, number NCT00976989. - RESULTS: Three-year Kaplan-Meier survival estimates for disease-free survival (DFS) were 87% (95% confidence interval: 79-95), 88% (80-96) and 90% (82-97) in groups A-C, respectively. Progression-free survival (PFS) rates were 89% (81-96), 89% (81-96) and 87% (80-95). DFS hazard ratio for total pathological complete response (tpCR) versus no tpCR was 0.27 (0.11-0.64). During post-treatment follow-up, 2/72 (2.8%), 3/75 (4.0%) and 4/76 (5.4%) patients in groups A-C had any-grade left ventricular systolic dysfunction; eight (11.1%), 12 (16.0%) and nine (11.8%) patients experienced left ventricular ejection fraction declines ≥10% from baseline to <50%. - CONCLUSIONS: Long-term DFS and PFS were similar between groups. Patients who achieved tpCR had improved DFS. No new safety signals were identified. | ||
| 650 | 4 | |a Adult | |
| 650 | 4 | |a Aged | |
| 650 | 4 | |a Aged, 80 and over | |
| 650 | 4 | |a Anthracyclines | |
| 650 | 4 | |a Antibodies, Monoclonal, Humanized | |
| 650 | 4 | |a Antineoplastic Combined Chemotherapy Protocols | |
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a Breast Neoplasms | |
| 650 | 4 | |a Cardiotoxicity | |
| 650 | 4 | |a Clinical efficacy | |
| 650 | 4 | |a Disease-free survival | |
| 650 | 4 | |a Female | |
| 650 | 4 | |a Heart | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Middle Aged | |
| 650 | 4 | |a Neoadjuvant therapy | |
| 650 | 4 | |a Pertuzumab | |
| 650 | 4 | |a Safety | |
| 650 | 4 | |a Stroke Volume | |
| 650 | 4 | |a Trastuzumab | |
| 650 | 4 | |a Ventricular Function, Left | |
| 700 | 1 | |a Chia, Stephen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hickish, Tamas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Harvey, Vernon |e VerfasserIn |4 aut | |
| 700 | 1 | |a Eniu, Alexandru |e VerfasserIn |4 aut | |
| 700 | 1 | |a Waldron-Lynch, Maeve |e VerfasserIn |4 aut | |
| 700 | 1 | |a Eng-Wong, Jennifer |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kirk, Sarah |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cortes, Javier |e VerfasserIn |0 (DE-588)142653705 |0 (DE-627)638445590 |0 (DE-576)332633640 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 89(2018), Seite 27-35 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer |
| 773 | 1 | 8 | |g volume:89 |g year:2018 |g pages:27-35 |g extent:9 |a Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer |
| 951 | |a AR | ||
| 992 | |a 20200406 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910100 |e 910000PS109972554 |e 910100PS109972554 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1694146022 |e 3619462178 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study","subtitle":"evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer","title_sort":"Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"eki":["1694146022"],"doi":["10.1016/j.ejca.2017.10.021"]},"physDesc":[{"extent":"9 S."}],"relHost":[{"part":{"volume":"89","year":"2018","text":"89(2018), Seite 27-35","pages":"27-35","extent":"9"},"language":["eng"],"pubHistory":["28.1992 -"],"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancerEuropean journal of cancer","corporate":[{"role":"isb","display":"European Organization for Research on Treatment of Cancer"},{"role":"isb","display":"European Association for Cancer Research"},{"role":"isb","display":"European School of Oncology"}],"titleAlt":[{"title":"EJC online"}],"recId":"266883400","id":{"issn":["1879-0852"],"eki":["266883400"],"zdb":["1468190-0"]},"title":[{"title":"European journal of cancer","title_sort":"European journal of cancer"}],"origin":[{"dateIssuedKey":"1992","publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]","publisher":"Elsevier ; Pergamon Press","dateIssuedDisp":"1992-"}]}],"origin":[{"dateIssuedDisp":"January 2018","dateIssuedKey":"2018"}],"language":["eng"],"name":{"displayForm":["Andreas Schneeweiss, Stephen Chia, Tamas Hickish, Vernon Harvey, Alexandru Eniu, Maeve Waldron-Lynch, Jennifer Eng-Wong, Sarah Kirk, Javier Cortés"]},"recId":"1694146022","person":[{"display":"Schneeweiss, Andreas","given":"Andreas","family":"Schneeweiss","role":"aut"},{"given":"Stephen","display":"Chia, Stephen","family":"Chia","role":"aut"},{"role":"aut","family":"Hickish","display":"Hickish, Tamas","given":"Tamas"},{"given":"Vernon","display":"Harvey, Vernon","family":"Harvey","role":"aut"},{"given":"Alexandru","display":"Eniu, Alexandru","family":"Eniu","role":"aut"},{"display":"Waldron-Lynch, Maeve","given":"Maeve","role":"aut","family":"Waldron-Lynch"},{"display":"Eng-Wong, Jennifer","given":"Jennifer","role":"aut","family":"Eng-Wong"},{"family":"Kirk","role":"aut","display":"Kirk, Sarah","given":"Sarah"},{"given":"Javier","display":"Cortes, Javier","role":"aut","family":"Cortes"}],"note":["Gesehen am 06.04.2020"]} | ||
| SRT | |a SCHNEEWEISLONGTERMEF2018 | ||